Secondary amyloidosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(5 intermediate revisions by the same user not shown)
Line 4: Line 4:


==Overview==
==Overview==
In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in [[organs]], causing [[Multiple organ dysfunction syndrome|organ dysfunction]] and eventually death. [[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]]. In primary amyloidosis, the [[survival rate]] depends upon the type of [[Organ (anatomy)|organ]] involvement and the [[hematological]] response to treatment.
In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in [[organs]], causing [[Multiple organ dysfunction syndrome|organ dysfunction]] and eventually death. [[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]]. [[Prognosis]] is poor and 5-years [[survival rate]] is 51.3%.[[Infection]] and [[renal failure]] are the most common cause of death.
 
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==


=== Natural History ===
=== Natural History ===
*In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in the organs, causing organ dysfunction and eventually death.<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref><ref name="pmid11677276">{{cite journal |vauthors=Khan MF, Falk RH |title=Amyloidosis |journal=Postgrad Med J |volume=77 |issue=913 |pages=686–93 |date=November 2001 |pmid=11677276 |pmc=1742163 |doi= |url=}}</ref>
*In amyloidosis, insoluble fibrils of [[amyloid]] are deposited in the organs, causing organ dysfunction.<ref name="LachmannGoodman2007">{{cite journal|last1=Lachmann|first1=Helen J.|last2=Goodman|first2=Hugh J.B.|last3=Gilbertson|first3=Janet A.|last4=Gallimore|first4=J. Ruth|last5=Sabin|first5=Caroline A.|last6=Gillmore|first6=Julian D.|last7=Hawkins|first7=Philip N.|title=Natural History and Outcome in Systemic AA Amyloidosis|journal=New England Journal of Medicine|volume=356|issue=23|year=2007|pages=2361–2371|issn=0028-4793|doi=10.1056/NEJMoa070265}}</ref>
*[[Patient|Patients]] with amyloidosis may eventually suffer from [[heart failure]], [[nephrotic syndrome]], [[hepatomegaly]] and [[peripheral neuropathy]].
*[[Patient|Patients]] with amyloidosis may eventually suffer from [[nephrotic syndrome]], [[renal failure]], and [[death]].


===Complications===
===Complications===
 
*In patients with amyloidosis, the most frequent [[complications]] include:<ref name="pmid26155101">{{cite journal |vauthors=Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA |title=Primary systemic amyloidosis as a real diagnostic challenge - case study |journal=Cent Eur J Immunol |volume=39 |issue=1 |pages=61–6 |date=2014 |pmid=26155101 |pmc=4439975 |doi=10.5114/ceji.2014.42126 |url=}}</ref>
In patients with amyloidosis, the most frequent [[complications]] include:<ref name="pmid26155101">{{cite journal |vauthors=Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA |title=Primary systemic amyloidosis as a real diagnostic challenge - case study |journal=Cent Eur J Immunol |volume=39 |issue=1 |pages=61–6 |date=2014 |pmid=26155101 |pmc=4439975 |doi=10.5114/ceji.2014.42126 |url=}}</ref>
**[[Nephrotic syndrome]], the most common
 
**[[Hepatomegaly]]
*[[Heart failure]]
**[[Peripheral neuropathy]] 
*[[Nephrotic syndrome]]
**[[Heart failure]]
*[[Hepatomegaly]]
*[[Peripheral neuropathy]] 
 
===Prognosis===
===Prognosis===
* Prognosis is not good and 5-years survival rate is 51.3%.<ref name="pmid25364365">{{cite journal |vauthors=Ahbap E, Kara E, Sahutoglu T, Basturk T, Koc Y, Sakaci T, Sevinc M, Akgol C, Ucar ZA, Kayalar AO, Bayraktar F, Ozagari AA, Unsal A |title=Outcome of 121 patients with renal amyloid a amyloidosis |journal=J Res Med Sci |volume=19 |issue=7 |pages=644–9 |date=July 2014 |pmid=25364365 |pmc=4214024 |doi= |url=}}</ref>
* [[Prognosis]] is poor and 5-years [[survival rate]] is 51.3%.<ref name="pmid25364365">{{cite journal |vauthors=Ahbap E, Kara E, Sahutoglu T, Basturk T, Koc Y, Sakaci T, Sevinc M, Akgol C, Ucar ZA, Kayalar AO, Bayraktar F, Ozagari AA, Unsal A |title=Outcome of 121 patients with renal amyloid a amyloidosis |journal=J Res Med Sci |volume=19 |issue=7 |pages=644–9 |date=July 2014 |pmid=25364365 |pmc=4214024 |doi= |url=}}</ref>
* Following factors are associated with higher rates of mortality:
* Following factors are associated with higher rates of [[mortality]]:
** Older age
** Older age
** Male gender
** Male gender
** lower BMI
** lower [[BMI]]
** Lower GFR
** Lower [[GFR]]
** Lower serum albumin and calcium
** Lower serum [[albumin]] and [[calcium]]
** Higher levels of phosphor with intact parathyroid hormone and proteinuria 
** Higher levels of [[phosphor]] with intact [[parathyroid hormone]]
* It has been reported that, survival rate is not affected by the underlying etiology.<ref name="pmid29173691">{{cite journal |vauthors=Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, Isiktas E, Oruc A, Celikci S, Arslan I, Sahin AB, Güllülü M |title=Clinical outcomes and survival in AA amyloidosis patients |journal=Rev Bras Reumatol Engl Ed |volume=57 |issue=6 |pages=535–544 |date=2017 |pmid=29173691 |doi=10.1016/j.rbre.2017.02.002 |url=}}</ref>
* [[Infection]] and [[renal failure]] are the most common cause of death.
* Median [[survival]] has been reported between 6 to 9 years.<ref name="LachmannGoodman2007">{{cite journal|last1=Lachmann|first1=Helen J.|last2=Goodman|first2=Hugh J.B.|last3=Gilbertson|first3=Janet A.|last4=Gallimore|first4=J. Ruth|last5=Sabin|first5=Caroline A.|last6=Gillmore|first6=Julian D.|last7=Hawkins|first7=Philip N.|title=Natural History and Outcome in Systemic AA Amyloidosis|journal=New England Journal of Medicine|volume=356|issue=23|year=2007|pages=2361–2371|issn=0028-4793|doi=10.1056/NEJMoa070265}}</ref>
* The most important predictable factor for development of [[renal failure]] and death is higher production of SAA.
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 19:22, 31 October 2019

Secondary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Secondary amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Secondary amyloidosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Secondary amyloidosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Secondary amyloidosis natural history, complications and prognosis

CDC on Secondary amyloidosis natural history, complications and prognosis

Secondary amyloidosis natural history, complications and prognosis in the news

Blogs on Secondary amyloidosis natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Secondary amyloidosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Sahar Memar Montazerin, M.D.[3]

Overview

In amyloidosis, insoluble fibrils of amyloid are deposited in organs, causing organ dysfunction and eventually death. Patients with amyloidosis may eventually suffer from heart failure, nephrotic syndrome, hepatomegaly and peripheral neuropathy. Prognosis is poor and 5-years survival rate is 51.3%.Infection and renal failure are the most common cause of death.

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

References

  1. 1.0 1.1 Lachmann, Helen J.; Goodman, Hugh J.B.; Gilbertson, Janet A.; Gallimore, J. Ruth; Sabin, Caroline A.; Gillmore, Julian D.; Hawkins, Philip N. (2007). "Natural History and Outcome in Systemic AA Amyloidosis". New England Journal of Medicine. 356 (23): 2361–2371. doi:10.1056/NEJMoa070265. ISSN 0028-4793.
  2. Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA (2014). "Primary systemic amyloidosis as a real diagnostic challenge - case study". Cent Eur J Immunol. 39 (1): 61–6. doi:10.5114/ceji.2014.42126. PMC 4439975. PMID 26155101.
  3. Ahbap E, Kara E, Sahutoglu T, Basturk T, Koc Y, Sakaci T, Sevinc M, Akgol C, Ucar ZA, Kayalar AO, Bayraktar F, Ozagari AA, Unsal A (July 2014). "Outcome of 121 patients with renal amyloid a amyloidosis". J Res Med Sci. 19 (7): 644–9. PMC 4214024. PMID 25364365.
  4. Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, Isiktas E, Oruc A, Celikci S, Arslan I, Sahin AB, Güllülü M (2017). "Clinical outcomes and survival in AA amyloidosis patients". Rev Bras Reumatol Engl Ed. 57 (6): 535–544. doi:10.1016/j.rbre.2017.02.002. PMID 29173691.


Template:WH Template:WS